The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Allergan Generics

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

Gallaher Group plc

Advised Gallaher Group plc, the world’s fifth largest tobacco company, on a recommended cash offer from Japan Tobacco Inc

Coal and Allied Industries Limited

Advised Coal and Allied Industries Limited, an Australian based coal mining company, in relation to an acquisition proposal from Rio Tinto Limited and Mitsubishi Corporation to acquire all the outstanding shares in the company not already held by Rio Tinto and Mitsubishi

Frutarom

Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition

Lion Nathan

Advised Lion Nathan, a leading brewery in Australia, on the sale of its remaining 54% stake to Kirin Holdings, a leading beverage company in Japan

Aegis Group plc

Advised Aegis Group plc, a leading global media and digital communications agency, on its sale to Dentsu Inc., the leading advertising group in Asia

Nikko Cordial Corporation

Advised Nikko Cordial, one of Japan’s largest securities firms, on its share exchange with Citigroup Inc., which resulted in Citigroup’s acquisition of the remaining 32% of Nikko Cordial that it did not already own

EMOBILE Ltd.

Advised the Independent Committee of eAccess Ltd., Japan's largest DSL wholesaler, on its business combination through a share exchange with EMOBILE, Ltd., the leading mobile data communications provider in Japan

PGM Holdings K.K. (majority owned by Lone Star Funds)

Advised Heiwa Corporation, a leading provider of pachinko amusement machines, on the tender offer to acquire 80.5% of PGM Holdings K.K., one of the largest golf club owners and operators in Japan, including 64.2% Lone Star Funds’ holding

Lucozade & Ribena brands (owned by GSK)

Advised GlaxoSmithKline, the UK listed international pharmaceutical and consumer company, on the sale of its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd

TOWER Australia Group Limited

Advised TOWER Australia Group Limited, the largest mono-line life insurance company in Australia, in relation to the offer from The Dai-ichi Life Insurance Company, Limited to acquire all of the shares in TOWER that it does not already own by way of a scheme of arrangement

Kenedix

Advising Kenedix, one of the largest Japanese independent real estate asset managers, on its acquisition by Sumitomo Mitsui Finance and Leasing, one of the largest Japanese leasing companies

Yakult

Advised Danone, a leading global food & beverage company, on renewing its strategic partnership with Yakult, a global leader in probiotic beverages, as well as the sale of part of its stake in Yakult

LIXIL VIVA

Advising Arcland Sakamoto, a leading owner and operator of large home centers, on the acquisition of LIXIL VIVA, a leading owner and operator of large home centers and a listed subsidiary of LIXIL Group, a leading Japanese manufacturer of building and housing materials

7-Eleven, Inc.

Advised the special committee of 7-Eleven, Inc. in connection with its evaluation of an unsolicited tender offer commenced by Seven-Eleven Japan Co., Ltd

Megapolis Distribution

Advised Japan Tobacco Inc in connection with the acquisition of a minority stake in Megapolis Distribution B.V., Russia’s leading tobacco distributor

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)

ITX (Mobile Phone Retailing Business)

Advised Japan Industrial Partners, a leading private equity firm in Japan, on the acquisition of mobile phone retailing business from ITX, a mobile phones marketer and distributor in Japan

US rights to 37 approved and 5 pipeline generic products

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
Haleon plc’s Nicotine Replacement Therapy Business (ex-US)

Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories

Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion

Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion

US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

Suncorp Group Limited’s Australian Life Insurance Business

Advised TAL, Australia’s largest and leading insurance business that is 100% owned by Dai-ichi Life of Japan, on the acquisition of Suncorp Group Limited’s Australian Life Insurance business

Lion’s stake in Warrnambool Cheese and Butter Factory Company

Advised Lion (an Australian subsidiary of Kirin), on the sale of its strategic stake in Warrnambool Cheese and Butter Factory to Canadian-based Saputo, under its all cash takeover offer

Advantage Resourcing America, Inc. & Advantage Resourcing Europe B.V.

Advised Recruit Co. Ltd, a leading staffing and publishing company in Japan, on the acquisition of all outstanding shares of Advantage Resourcing America, Inc. & Advantage Resourcing Europe B.V, wholly owned by investment vehicles affiliated with Cerberus Capital Management L.P.